Funds and ETFs Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 03:20:53 2024-05-08 pm EDT 5-day change 1st Jan Change
305.6 USD +1.76% Intraday chart for Amgen Inc. +10.21% +6.13%

ETFs positioned on Amgen Inc.

Name Weight AuM 1st Jan change Investor Rating
0.71% 330 M€ -.--% -
0.67% 219 M€ +17.17% -
0.67% 1,448 M€ -.--% -
0.67% 0 M€ +12.54%
0.66% 2 M€ +14.69% -
0.66% 8 M€ +5.48% -
0.65% 0 M€ +6.87%
0.61% 0 M€ +7.49%
0.58% 2 M€ +21.73% -
0.57% 0 M€ +17.41% -
0.56% 273 M€ -.--%
0.56% 655 M€ -.--% -
0.56% 1,174 M€ +23.54%
0.56% 5 M€ -.--% -
0.55% 0 M€ +7.94%
0.52% 92 M€ +0.06% -
0.52% 0 M€ +4.51% -
0.50% 0 M€ +18.29% -
0.49% 1,848 M€ +18.39% -
0.49% 559 M€ +14.30% -
0.49% 0 M€ +7.81%
0.48% 0 M€ +6.95%
0.48% 276 M€ +11.40% -
0.46% 0 M€ -.--% -
0.46% 0 M€ +8.83% -
0.46% 0 M€ +11.08%
0.45% 0 M€ +3.67% -
0.45% 414 M€ +11.37% -
0.45% 1,006 M€ -.--% -
0.44% 6 M€ +17.98% -
0.44% 0 M€ +6.13% -
0.42% 0 M€ +3.41% -
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
300.3 USD
Average target price
313.3 USD
Spread / Average Target
+4.33%
Consensus
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. Funds and ETFs Amgen Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW